Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GGC Supplementation in Early Parkinson's Disease
NCT07064005Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gamma-Glutamylcysteine in Parkinson's disease (PD). Primary endpoints: Brain glutathione levels at 12 months, Brain iron levels at 12 months and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
gamma-Glutamylcysteine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07064005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064005.